Xu Teng, Zhu Ying, Xiong Yujuan, Ge Yi-Yuan, Yun Jing-Ping, Zhuang Shi-Mei
Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Guangzhou, PR China.
Hepatology. 2009 Jul;50(1):113-21. doi: 10.1002/hep.22919.
Growing evidence indicates that deregulation of microRNAs (miRNAs) contributes to tumorigenesis. Down-regulation of miR-195 has been observed in various types of cancers. However, the biological function of miR-195 is still largely unknown. In this study we aimed to elucidate the pathophysiologic role of miR-195. Our results showed that miR-195 expression was significantly reduced in as high as 85.7% of hepatocellular carcinoma (HCC) tissues and in all of the five HCC cell lines examined. Moreover, introduction of miR-195 dramatically suppressed the ability of HCC and colorectal carcinoma cells to form colonies in vitro and to develop tumors in nude mice. Furthermore, ectopic expression of miR-195 blocked G(1)/S transition, whereas inhibition of miR-195 promoted cell cycle progression. Subsequent investigation characterized multiple G(1)/S transition-related molecules, including cyclin D1, CDK6, and E2F3, as direct targets of miR-195. Silencing of cyclin D1, CDK6, or E2F3 phenocopied the effect of miR-195, whereas overexpression of these proteins attenuated miR-195-induced G(1) arrest. In addition, miR-195 significantly repressed the phosphorylation of Rb as well as the transactivation of downstream target genes of E2F. These results imply that miR-195 may block the G(1)/S transition by repressing Rb-E2F signaling through targeting multiple molecules, including cyclin D1, CDK6, and E2F3.
Our data highlight an important role of miR-195 in cell cycle control and in the molecular etiology of HCC, and implicate the potential application of miR-195 in cancer therapy.
越来越多的证据表明,微小RNA(miRNA)失调与肿瘤发生有关。在各种类型的癌症中均观察到miR-195表达下调。然而,miR-195的生物学功能仍大多未知。在本研究中,我们旨在阐明miR-195的病理生理作用。我们的结果显示,在高达85.7%的肝细胞癌(HCC)组织以及所有检测的5种HCC细胞系中,miR-195表达均显著降低。此外,导入miR-195可显著抑制HCC和结肠癌细胞在体外形成集落以及在裸鼠体内形成肿瘤的能力。此外,miR-195的异位表达阻断了G(1)/S期转换,而抑制miR-195则促进细胞周期进程。随后的研究鉴定了多个与G(1)/S期转换相关的分子,包括细胞周期蛋白D1、细胞周期蛋白依赖性激酶6(CDK6)和E2F3,作为miR-195的直接靶标。沉默细胞周期蛋白D1、CDK6或E2F3可模拟miR-195的作用,而这些蛋白的过表达则减弱了miR-195诱导的G(1)期阻滞。此外,miR-195显著抑制Rb的磷酸化以及E2F下游靶基因的反式激活。这些结果表明,miR-195可能通过靶向包括细胞周期蛋白D1、CDK6和E2F3在内地多个分子抑制Rb-E2F信号传导,从而阻断G(1)/S期转换。
我们的数据突出了miR-195在细胞周期调控以及HCC分子病因学中的重要作用,并提示miR-195在癌症治疗中的潜在应用。